http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00DrUKMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngDrUKM2017-09-17 10:21:402017-09-18 10:26:31$SGEN - Good time to buy based on Adcetris label expansion
http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00SMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngSM2017-09-15 15:33:482017-09-23 16:12:04Time To Book Profit In AbbVie Stock Despite Patent Win
http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00SMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngSM2017-09-15 14:07:272017-09-15 14:07:27Amgen needs to get lucky with Repatha
http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00DrUKMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngDrUKM2017-09-09 07:36:552017-09-15 08:30:19AstraZeneca: Is It Investable After Imfinzi Failure?
http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00SMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngSM2017-09-09 07:02:262017-09-15 07:17:27Opko: Why I Am Cautiously Bullish
http://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.png00SMhttp://avisolcapital.com/wp-content/uploads/2017/03/acplogo-80x78.pngSM2017-09-01 14:44:322017-09-14 14:51:11Novo Nordisk Offers Some Sweet Dividends With Its Strong Diabetes Portfolio
